Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma GroupFRA:LUP +5.17%52 3-Year ROIIC % is 2.70 as of Dec. 2025, which is 34% below its 10-year median of 4.09. GuruFocus rates FRA:LUP with a GF Score™ of 52/100 and a GF Value™ of €0.35 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Luye Pharma Group ranks worse than 52.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Luye Pharma Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2.70%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Luye Pharma Group's 3-Year ROIIC % or its related term are showing as below:
FRA:LUP's 3-Year ROIIC % is ranked worse than 52.11% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs FRA:LUP: 2.70
Luye Pharma Group (FRA:LUP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Luye Pharma Group 3-Year ROIIC % Related Terms
Luye Pharma Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Luye Pharma Group (FRA:LUP) has a 3-Year ROIIC % of 2.70 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Luye Pharma Group and its competitors. This is 34% below median its historical median of 4.09. According to the industry distribution chart, Luye Pharma Group ranks #493 out of 946 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Luye Pharma Group's 3-Year ROIIC % too high?
Luye Pharma Group's current 3-Year ROIIC % of 2.70 is 34% below median its 10-year median of 4.09. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Luye Pharma Group's value of 2.70 is 25.7% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #493 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #493 out of 946 companies for 3-Year ROIIC %. This places Luye Pharma Group in the lower half of its industry. The industry median 3-Year ROIIC % is 3.64. Luye Pharma Group's value of 2.70 is 25.7% below this benchmark. While the company's 10-year median is 4.09 vs. the industry median of 3.64, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current 3-Year ROIIC % of 2.70 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current 3-Year ROIIC % is 2.70, which is 34% below median its own 10-year median of 4.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.35, compared to a current price of €0.24 — trading 30.3% below its estimated fair value. The current 3-Year ROIIC % is 2.70, which is 34% below median its 10-year median of 4.09 and 25.7% below the Drug Manufacturers industry median of 3.64. Luye Pharma Group's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current 3-Year ROIIC % is 2.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.24 is trading 30.3% below its estimated GF Value™ of €0.35.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
3-Year ROIIC %: 2.70 (34% below median its 10-year median of 4.09)
GF Value™: €0.35 vs. price of €0.24 (30.3% below fair value)
Industry Position: 25.7% below the Drug Manufacturers median (#493 of 946)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
52GF Score
Get the complete analysis for FRA:LUP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
